N@N

InterMune To Release First Quarter Financial Results On April 24

^{Published on 2013-04-17 05:16:02 - Market Wire}
 

InterMune To Release First Quarter Financial Results On April 24 -- BRISBANE, Calif., April 17, 2013 /PRNewswire/ --

[ ]

[ Download image ]

BRISBANE, Calif., April 17, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: [ ITMN ]) today announced that it will release its first quarter 2013 financial results at the close of the U.S. markets on Wednesday, April 24, 2013.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

(Logo: [ http://photos.prnewswire.com/prnh/20120827/SF62570LOGO ])

Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1 212-271-4651 (international), conference ID#21655193.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call.  To access the live webcast, please log on to the company's website at [ www.intermune.com ] at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID#21655193. 

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet^® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit [ www.intermune.com ].

SOURCE InterMune, Inc.